Genmab — April 2021

E_L

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma https://ashpublications.org/bloodadvances/article/5/8/2165/475774/Potent-preclinical-activity-of-HexaBody-DR5-DR5-in

Plimsoller

Gad vide hvor mange penge Biden egentlig tror at han kan få ind ved at indføre højere beskatning af kapitalindkomster over 1 mio. Jeg har ikke selv set det, men det lyder lidt som en crowd pleaser som nogle af de forsleg vi kender herhjemme. Desuden så har befolkningsgruppen med så høje aktieindkomster råd til en god revisor, og det betyder en del i USA.

Bulder

Nice E L. So if they can't pursue hexacd38 in MM, they have dr5/dr5 in stead.

E_L

very exciting!

Darvin

Thanks E L

GeorgeBest

Presume they can only use it for patients not on dara anymore? Probably only later lines of treatment?

E_L

you mean from a JNJ perspective?

Darvin

They write "cytotoxicity can be enhanced via combination with bortezomib, daratumumab, or lenalidomide"

E_L

I think they can use other drugs for MM, as long as it isn't
CD38

GeorgeBest

Yes okay, makes sence

E_L

i think it is funny how they write 'Daratumumab showed additive effects when combined with HexaBody-DR5/DR5' ; as in: the big multiple blockbuster could help a bit, instead of writing DR5 could help Dara a bit lol

E_L

but anyway, even more interested to see the first clinical data now in solids, to see if this isn't too toxic in human

JørgenVarnæs

GEN said update on DR5 during 2021 - and primary completion in dec21. Do we know anything more specific?

kkjoel

Was just about to ask the same
...

Sukkeralf

No

JørgenVarnæs

Asco er vel for tidligt? Er der en konference i efteråret, der passer?

Sukkeralf

ESMO er vel bedste bud - plejer at ligge i september

Sukkeralf

Det kan evt også blot være en opdatering hos Genmab selv - specielt hvis data er lidt mudrede

JørgenVarnæs

Lyder rigtigt

StockBull

mon ikke vi skal lidt op på den helt korte bane 5 min grafen indikere op på min skærm